Erik C. Schimmel

Arnhem, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patients.

Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patients.

Journal: Journal of the National Cancer Institute

Published: September 12, 2025

Predicting long-term absolute risk of lung cancer in patients with Hodgkin lymphoma.

Predicting long-term absolute risk of lung cancer in patients with Hodgkin lymphoma.

Journal: Journal of the National Cancer Institute

Published: September 12, 2025

Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal: Journal of the National Cancer Institute

Published: September 08, 2025

Development of a national indication protocol for proton therapy in patients with seminoma testis to reduce the risk on subsequent primary cancers.

Development of a national indication protocol for proton therapy in patients with seminoma testis to reduce the risk on subsequent primary cancers.

Journal: International journal of radiation oncology, biology, physics

Published: August 25, 2025

Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patients.

Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patients.

Journal: Brachytherapy

Published: August 10, 2025

Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.

Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 15, 2024

Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.

Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.

Journal: ESMO open

Published: October 13, 2023

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: February 29, 2016

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.

Journal: The Lancet. Oncology

Published: October 29, 2015

Correction to Lancet Oncol 2015; 16: 274.

Correction to Lancet Oncol 2015; 16: 274.

Journal: The Lancet. Oncology

Published: March 11, 2015

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

Journal: The Lancet. Oncology

Published: February 07, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026